BlinkLab Enters Academic Research Agreement With Dutch Research Center

MT Newswires Live

May 19

BlinkLab (ASX:BB1) entered into an academic research agreement with Erasmus University Medical Center in the Netherlands to investigate treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare disorder associated with neurodevelopmental and behavioral symptoms, including autism, according to a Tuesday Australian bourse filing.

The study evaluates behavioral and neurodevelopmental function before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy in the syndrome.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2636885172"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2636885172\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2636885172?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636885172","market":"us","top_or_hot":-1,"title":"BlinkLab Enters Academic Research Agreement With Dutch Research Center","media":"MT Newswires Live","content":"<html><body><p> BlinkLab (ASX:BB1) entered into an academic research agreement with Erasmus University Medical Center in the Netherlands to investigate treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare disorder associated with neurodevelopmental and behavioral symptoms, including autism, according to a Tuesday Australian bourse filing.</p><p>The study evaluates behavioral and neurodevelopmental function before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy in the syndrome.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlinkLab Enters Academic Research Agreement With Dutch Research Center</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlinkLab Enters Academic Research Agreement With Dutch Research Center\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BlinkLab (ASX:BB1) entered into an academic research agreement with Erasmus University Medical Center in the Netherlands to investigate treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare disorder associated with neurodevelopmental and behavioral symptoms, including autism, according to a Tuesday Australian bourse filing.</p><p>The study evaluates behavioral and neurodevelopmental function before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy in the syndrome.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BB1.AU","symbol_name":"Blinklab Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636885172","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636885172","pubTimestamp":1779156023,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BlinkLab  entered into an academic research agreement with Erasmus University Medical Center in the Netherlands to investigate treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare disorder associated with neurodevelopmental and behavioral symptoms, including autism, according to a Tuesday Australian bourse filing.The study evaluates behavioral and neurodevelopmental function before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy in the syndrome.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BB1.AU":"Blinklab Ltd","BK7094":"医疗保健技术"},"translate_title":"BlinkLab与荷兰研究中心签订学术研究协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BB1.AU":1},"content_text":"BlinkLab (ASX:BB1) entered into an academic research agreement with Erasmus University Medical Center in the Netherlands to investigate treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare disorder associated with neurodevelopmental and behavioral symptoms, including autism, according to a Tuesday Australian bourse filing.The study evaluates behavioral and neurodevelopmental function before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy in the syndrome.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}